Open an account

VivoSim Labs

VIVS · NASDAQ

$0.1713+$0.0138 (+8.76%)TodayMarket closed ·
Prev close $0.1575

About VIVS

VivoSim Labs, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 13 full-time employees. The company went IPO on 2013-08-02. The firm offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The firm offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. The company uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The firm also advances product candidates to treat inflammatory bowel disease (IBD) discovered and developed using its complex human tissue intestinal models.

Employees
13
Headquarters
San Diego, California
Listed
Aug 2, 2013
Sector
Health Care
Industry
Biotechnology
Website
organovo.com

VIVS key statistics

Market cap
2.60M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
776.94K
Volume
692.30K
Open price
$0.16
High today
$0.1847
Low today
$0.1592
52 Week high
$3.40
52 Week low
$0.1495

VivoSim Labs (VIVS) at a glance

As of Oct 20, 2026, VivoSim Labs (VIVS) shares are priced at $0.1713, giving the company a market cap of 2.60M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.1592 and $0.1847. The current price is 7.6% above the day's low and 7.3% below its high.

Volume so far is 692.30K shares, in line with the average of 776.94K shares a day.

Over the past year VivoSim Labs has ranged from $0.1495 to $3.40, and now sits 1% of the way up that range.

VivoSim Labs met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q4 FY25 it reported -$2.21 per share against an estimate of -$0.1938.

VIVS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 26.6% on average.

  1. Q3 FY23: reported -$0.40 per share against an estimate of $0.00
  2. Q2 FY24: reported -$5.52 per share against an estimate of -$5.26
  3. Q3 FY24: reported -$4.80 per share against an estimate of -$5.39
  4. Q4 FY24: reported -$3.48 per share against an estimate of -$5.14
  5. Q1 FY25: reported -$2.76 per share against an estimate of -$4.04
  6. Q2 FY25: reported -$1.68 per share against an estimate of -$3.18
  7. Q3 FY25: reported -$2.29 per share against an estimate of -$2.57
  8. Q4 FY25: reported -$2.21 per share against an estimate of -$0.1938

VIVS news

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Lekha Gupta

    Why Is VivoSim Labs Stock Falling Thursday?

  • Avi Kapoor

    Why JB Hunt Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

  • Press releaseGlobe Newswire

    Three Biotechs Deliver Catalysts to Watch

  • Avi Kapoor

    Gold Tumbles Over 6%; Apple Posts Upbeat Earnings

  • Avi Kapoor

    Dow Falls Over 100 Points; Verizon Earnings Top Views

  • Market-Moving News for January 30th

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

Similar companies

Companies in the same industry as VivoSim Labs

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.